Welcome to the international HTA database

Showing [24125 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	NIHR Health Services and Delivery Research programme	Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025	NIHR Health Services and Delivery Research programme	Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025	NIHR Health Technology Assessment programme	Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial
2025	Agency for Care Effectiveness (ACE)	Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025	NIHR Health Technology Assessment programme	Learnings from the establishment and delivery of the UK Collaborative Paediatric Palliative Care Research Network
2025	Agency for Care Effectiveness (ACE)	Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025	Swiss Federal Office of Public Health (FOPH)	Magnesium supplements for muscle cramps and for the prevention of recurrent urinary tract stones
2025	NIHR Health Technology Assessment programme	Establishing palliative care research partnerships in Northern Ireland
2025	Agency for Care Effectiveness (ACE)	Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Swiss Federal Office of Public Health (FOPH)	Point-of-care diagnostic tests
2025	NIHR Health Services and Delivery Research programme	Clinical and cost-effectiveness of paramedics working in general practice: a mixed-methods realist evaluation
2025	Agency for Care Effectiveness (ACE)	Atogepant and rimegepant for prophylaxis of migraine
2025	Swiss Federal Office of Public Health (FOPH)	Multigene-expression tests for breast cancer
2025	NIHR Health Services and Delivery Research programme	Optimisation of the deployment of automated external defibrillators in public places in England
2025	Agency for Care Effectiveness (ACE)	Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025	NIHR Health Technology Assessment programme	Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Food allergen-specific IgG4 (immunoglobulin G4) measurement by immunoassay]
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Blood levels testing of imatinib and its active metabolite by high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2025	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Asynchronous teledermatology as a mechanism for triage and patient referral between primary and specialty care and to support the diagnosis of dermatologic conditions]
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2025	National Institute for Health and Care Excellence (NICE)	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Autonomous diagnostic system (AI) for patients with diabetic retinopathy]
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2025	NIHR Health Services and Delivery Research programme	How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis
2025	National Institute for Health and Care Excellence (NICE)	Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of delayed antibiotic prescription in the treatment of acute upper respiratory tract infections]
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025	National Institute for Health and Care Excellence (NICE)	Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
2025	NIHR Health Technology Assessment programme	The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
2025	National Institute for Health and Care Excellence (NICE)	Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 802
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
2025	NIHR Health Services and Delivery Research programme	Community and hospital-based healthcare professionals perceptions of digital advance care planning for palliative and end-of-life care: a latent class analysis
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of scalp cooling to prevent chemotherapy-induced alopecia (CIA)]
2025	NIHR Health Technology Assessment programme	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025	Scottish Health Technologies Group (SHTG)	Vacuum bell device for people with pectus excavatum
2025	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025	Scottish Health Technologies Group (SHTG)	Artificial intelligence (AI) assisted endoscopy
2025	NIHR Health Technology Assessment programme	Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025	Scottish Health Technologies Group (SHTG)	Stability of prostate specific antigen (PSA) in blood samples
2025	NIHR Health Technology Assessment programme	Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025	NIHR Health Technology Assessment programme	Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025	NIHR Health Services and Delivery Research programme	The implementation of safety management systems in healthcare: a systematic review and international comparison
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2025	Gesundheit Osterreich GmbH (GOeG)	[Efficacy and safety of antibody therapies in early-stage Alzheimer's disease]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Bispecific and tumor-infiltrating T cell therapies: considerations for deployment in Quebec]
2025	Institute of Health Economics (IHE)	PET/CT capacity for cancer diagnosis and follow-up: rapid review
2025	NIHR Health Technology Assessment programme	Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT
2025	NIHR Health Technology Assessment programme	The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Dedicated staff for placement of indwelling urinary catheters
2025	Health Sciences Institute in Aragon (IACS)	Programme for the use of real world data in health technology assessment: using real-world data for health technology assessment
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[ADHD and driving performance]
2025	National Institute for Health and Care Excellence (NICE)	Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal). NICE technology appraisal guidance 1078
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Assesment of artificial intelligence´s diagnostic yield and security in cardiac monitoring using insertable cardiac monitors]
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025	National Institute for Health and Care Excellence (NICE)	Sparsentan for treating primary IgA nephropathy. NICE technology appraisal guidance 1074
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Alternative methods to coercive measures]
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prediction models in dental care - basis for the National Board of Health and Welfare’s mission to develop a national model for risk assessment in dental care]
2025	Agency for Care Effectiveness (ACE)	Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025	National Institute for Health and Care Excellence (NICE)	Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. NICE technology appraisal guidance 1073
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Effectiveness and complications of preimplantation genetic testing for aneuploidies (PGT-A) in in vitro fertilisation (IVF)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Appropriate use of cardiac monitoring in the emergency department]
2025	National Institute for Health and Care Excellence (NICE)	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1071
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Adaptive deep brain stimulation in Parkinson's disease]
2025	Agency for Care Effectiveness (ACE)	Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1072
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025	National Institute for Health and Care Excellence (NICE)	Spesolimab for treating generalised pustular psoriasis flares. NICE technology appraisal guidance 1070
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Phonocardiography to rule out coronary heart disease]
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025	National Institute for Health and Care Excellence (NICE)	Linzagolix for treating symptoms of endometriosis. NICE technology appraisal guidance 1067
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the update of the DMP “type 2 diabetes”]
2025	Agency for Care Effectiveness (ACE)	Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	National Institute for Health and Care Excellence (NICE)	Efgartigimod for treating antibody-positive generalised myasthenia gravis. NICE technology appraisal guidance 1069
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	Monitoring study protocol: left ventricular assist devices destination therapy
2025	NIHR Health Technology Assessment programme	Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
2025	Agency for Care Effectiveness (ACE)	Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025	National Institute for Health and Care Excellence (NICE)	Somapacitan for treating growth hormone deficiency in people 3 to 17 years. NICE technology appraisal guidance 1066
2025	Austrian Institute for Health Technology Assessment (AIHTA)	Exagamglogene autotemcel (Exa-cel, Casgevy®)
2025	Agency for Care Effectiveness (ACE)	Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025	National Institute for Health and Care Excellence (NICE)	Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. NICE interventional procedures guidance 805
2025	National Institute for Health and Care Excellence (NICE)	Targeted muscle reinnervation for managing limb amputation pain. NICE interventional procedures guidance 804
2025	National Institute for Health and Care Excellence (NICE)	Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. NICE interventional procedures guidance 803
2025	Health Information and Quality Authority (HIQA)	Evidence review of specialist cardiac services
2025	Austrian Institute for Health Technology Assessment (AIHTA)	[Reimbursement models and pricing of digital health technologies and telemonitoring applications – Rapid scoping review]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Delayed labour: Can non-drug interventions such as castor oil or acupuncture promote the birth process?]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Buccal cell sampling as a source of genetic material]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection – glofitamab (DLBCL)]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Routine practice data collection for brexucabtagene autoleucel (MCL): Review of the study protocol (Version 4.0) and statistical analysis plan (Version 4.0) – Sixth Addendum to Project A21-130]
2025	NIHR Health Technology Assessment programme	Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (NSCLC, second line or later) – Addendum to Project A24-128]
2025	NIHR Health Technology Assessment programme	Experiences of support to return to work after stroke: longitudinal case studies from RETAKE trial
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Systematic confounder identification in the indication of relapsing-remitting multiple sclerosis (RRMS)]
2025	NIHR Health Technology Assessment programme	Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map